BQ.1 accounted for an estimated 20.1 percent of cases in the week ending Nov. 12, up from 16.1 percent the week prior. BQ.1.1, which has one additional mutation, accounts for an estimated 24.1 percent of cases.
The strains — dubbed “escape variants” for their immune evasiveness — have quickly overtaken BA.5, which had been the nation’s dominant strain since early July.
The subvariants’ climbing prevalence is fueling concerns of a potential winter COVID-19 surge, though most experts predict any jump in infections would be less severe than the past two winter surges.
“This time of year last year we were optimistic. We were coming out of the delta wave, and it was steadily decreasing, and we went into Thanksgiving to wake up to omicron,” Jeremy Luban, MD, a physician-scientist at Amherst-based University of Massachusetts, told NPR. “So there is this sort of déjà vu feeling from last year.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
